Phio Pharmaceuticals Corp.
NCM: PHIOLive Quote
📈 ZcoreAI Score
Our AI model analyzes Phio Pharmaceuticals Corp.'s price action across multiple timeframes using regression channels and statistical scoring.
Get PHIO Z-Score →About Phio Pharmaceuticals Corp.
Healthcare
Biotechnology
Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was founded in 2003 and is based in King Of Prussia, Pennsylvania.
📊 Fundamental Analysis
Phio Pharmaceuticals Corp. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -69.9%, which indicates that capital utilization is currently under pressure.
At a current price of $1.21, PHIO currently trades near the bottom of its 52-week range (12%), indicating potential value or weakness (Range: $0.81 - $4.19).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Return on Equity
Weak
⚠️
Beta (Risk)
Moderate Volatility
Key Financials
Market Cap
$14.06M
Trailing P/E
--
Forward P/E
-1.95
Beta (5Y)
0.81
52W High
$4.19
52W Low
$0.81
Avg Volume
3.86M
Day High
Day Low